Fig. 2

Loss of SPRYD4 correlates with unfavorable clinicopathological characteristics and poor prognosis in CCA. A SPRYD4 expression of CCA was significantly correlated with tumor differentiation, lymphnode metastasis and TNM stage. B-C Kaplan–Meier analyses showed CCA patients with low expression of SPRYD4 had inferior OS (B) and DFS (C) than those with high expression in GPPH cohort. D-E Multivariate Cox regression analyses were performed to confirmed low expression of SPRYD4 was independent risk factor for OS (D) and DFS (E) of CCA patients from GPPH cohort. P-values were determined by χ2 tests or Fisher’s exact tests in A. The Hazard Ratios (HR) and P-values by the log-rank (Mantel-Cox) test are calculated in B-C. All * P-value < 0.05, ** P-value < 0.01